Clinical Trial

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-19; most recent amendment 2025-06-20.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-06-20
Trial Details
NCT Number NCT06896110
Lead Sponsor Andrew P. Groves
Conditions Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant, Gliosarcoma of Brain
Enrollment 34 participants
Start Date 2025-06-05
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-06-26